Search Results - "McLemore, Michael F"

Data-driven automated classification algorithms for acute health conditions: applying PheNorm to COVID-19 disease by Smith, Joshua C, Williamson, Brian D, Cronkite, David J, Park, Daniel, Whitaker, Jill M, McLemore, Michael F, Osmanski, Joshua T, Winter, Robert, Ramaprasan, Arvind, Kelley, Ann, Shea, Mary, Wittayanukorn, Saranrat, Stojanovic, Danijela, Zhao, Yueqin, Toh, Sengwee, Johnson, Kevin B, Aronoff, David M, Carrell, David S

“…Abstract Objectives Automated phenotyping algorithms can reduce development time and operator dependence compared to manually developed algorithms. One such…”
Get full text

Electronic health record-based predictive models for acute kidney injury screening in pediatric inpatients by Wang, Li, McGregor, Tracy L, Jones, Deborah P, Bridges, Brian C, Fleming, Geoffrey M, Shirey-Rice, Jana, McLemore, Michael F, Chen, Lixin, Weitkamp, Asli, Byrne, Daniel W, Van Driest, Sara L

“…Background Acute kidney injury (AKI) is common in pediatric inpatients and is associated with increased morbidity, mortality, and length of stay. Its early…”
Get full text

Acute kidney injury risk-based screening in pediatric inpatients: a pragmatic randomized trial by Van Driest, Sara L., Wang, Li, McLemore, Michael F., Bridges, Brian C., Fleming, Geoffrey M., McGregor, Tracy L., Jones, Deborah P., Shirey-Rice, Jana, Gatto, Cheryl L., Gay, James C., Byrne, Daniel W., Weitkamp, Asli, Roden, Dan M., Bernard, Gordon

“…Background Pediatric acute kidney injury (AKI) is common and associated with increased morbidity, mortality, and length of stay. We performed a pragmatic…”
Get full text

Is the Climb Worth the View? The Savings/Alert Ratio for Reducing Vitamin D Testing by Hendrickson, Chase D, McLemore, Michael F, Dahir, Kathryn M, Just, Shari, Shajani-Yi, Zahra, LeGrand, Joseph, Lehmann, Christoph U, Weitkamp, Asli

“…Despite guideline recommendations, vitamin D testing has increased substantially. Clinical decision support (CDS) presents an opportunity to reduce…”
Get full text

Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes by Khera, Rohan, Aminorroaya, Arya, Dhingra, Lovedeep Singh, Thangaraj, Phyllis M., Pedroso Camargos, Aline, Bu, Fan, Ding, Xiyu, Nishimura, Akihiko, Anand, Tara V., Arshad, Faaizah, Blacketer, Clair, Chai, Yi, Chattopadhyay, Shounak, Cook, Michael, Dorr, David A., Duarte-Salles, Talita, DuVall, Scott L., Falconer, Thomas, French, Tina E., Hanchrow, Elizabeth E., Kaur, Guneet, Lau, Wallis C.Y., Li, Jing, Li, Kelly, Liu, Yuntian, Lu, Yuan, Man, Kenneth K.C., Matheny, Michael E., Mathioudakis, Nestoras, McLeggon, Jody-Ann, McLemore, Michael F., Minty, Evan, Morales, Daniel R., Nagy, Paul, Ostropolets, Anna, Pistillo, Andrea, Phan, Thanh-Phuc, Pratt, Nicole, Reyes, Carlen, Richter, Lauren, Ross, Joseph S., Ruan, Elise, Seager, Sarah L., Simon, Katherine R., Viernes, Benjamin, Yang, Jianxiao, Yin, Can, You, Seng Chan, Zhou, Jin J., Ryan, Patrick B., Schuemie, Martijn J., Krumholz, Harlan M., Hripcsak, George, Suchard, Marc A.

“…Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular…”
Get full text

Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM by Khera, Rohan, Aminorroaya, Arya, Dhingra, Lovedeep Singh, Thangaraj, Phyllis M, Pedroso Camargos, Aline, Bu, Fan, Ding, Xiyu, Nishimura, Akihiko, Anand, Tara V, Arshad, Faaizah, Blacketer, Clair, Chai, Yi, Chattopadhyay, Shounak, Cook, Michael, Dorr, David A, Duarte-Salles, Talita, DuVall, Scott L, Falconer, Thomas, French, Tina E, Hanchrow, Elizabeth E, Kaur, Guneet, Lau, Wallis C Y, Li, Jing, Li, Kelly, Liu, Yuntian, Lu, Yuan, Man, Kenneth K C, Matheny, Michael E, Mathioudakis, Nestoras, McLeggon, Jody-Ann, McLemore, Michael F, Minty, Evan, Morales, Daniel R, Nagy, Paul, Ostropolets, Anna, Pistillo, Andrea, Phan, Thanh-Phuc, Pratt, Nicole, Reyes, Carlen, Richter, Lauren, Ross, Joseph S, Ruan, Elise, Seager, Sarah L, Simon, Katherine R, Viernes, Benjamin, Yang, Jianxiao, Yin, Can, You, Seng Chan, Zhou, Jin J, Ryan, Patrick B, Schuemie, Martijn J, Krumholz, Harlan M, Hripcsak, George, Suchard, Marc A

“…Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk of major adverse cardiovascular…”
Get full text

Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM by Khera, Rohan, Dhingra, Lovedeep Singh, Aminorroaya, Arya, Li, Kelly, Zhou, Jin J, Arshad, Faaizah, Blacketer, Clair, Bowring, Mary G, Bu, Fan, Cook, Michael, Dorr, David A, Duarte-Salles, Talita, DuVall, Scott L, Falconer, Thomas, French, Tina E, Hanchrow, Elizabeth E, Horban, Scott, Lau, Wallis CY, Li, Jing, Liu, Yuntian, Lu, Yuan, Man, Kenneth KC, Matheny, Michael E, Mathioudakis, Nestoras, McLemore, Michael F, Minty, Evan, Morales, Daniel R, Nagy, Paul, Nishimura, Akihiko, Ostropolets, Anna, Pistillo, Andrea, Posada, Jose D, Pratt, Nicole, Reyes, Carlen, Ross, Joseph S, Seager, Sarah, Shah, Nigam, Simon, Katherine, Wan, Eric YF, Yang, Jianxiao, Yin, Can, You, Seng Chan, Schuemie, Martijn J, Ryan, Patrick B, Hripcsak, George, Krumholz, Harlan, Suchard, Marc A

“…ObjectiveTo assess the uptake of second line antihyperglycaemic drugs among patients with type 2 diabetes mellitus who are receiving metformin.DesignFederated…”
Get full text